Abbott's antiretroviral Kaletra (lopinavir plus ritonavir) is facing generic competition in Ecuador after the government issued a compulsory licence, following a request from the ESKE Group, for ritonavir on 14 April. The R&D pharmaceutical industry has criticised the decision, saying it undermines the patent system.
In addition the Indian firm Matrix has requested a second compulsory licence for the same drug, which could follow soon,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?